Chinese investor Creat Group Corp.’s planned takeover of German blood plasma supplier Biotest AG is facing increased scrutiny from the U.S. government, according to people familiar with the matter, potentially putting the deal at risk.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
